100% Same
Salt CompositionEffectivenessStrength
with Substitute Medicine
Glimepiride 2mg + Metformin 500mg + Voglibose 0.2mg


WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)
Delivery by
In Treatment of Type 2 diabetes mellitus : Glimfra MV 2 Tablet ER is a medicine that helps to control high blood glucose (sugar) levels. It helps to slow down the breaking down of food in our intestine to simple glucose (sugar), thereby decreasing the rise in blood glucose levels after meals. It also helps get rid of extra glucose from your body through urine. Lowering blood glucose levels is an essential part of managing diabetes. If you can control the level, you will reduce the risk of getting any of the serious complications of diabetes such as kidney damage, eye damage, nerve problems and loss of limbs. Glimfra MV 2 Tablet ER will reduce the risk of dying from cardiovascular disease if you have type 2 diabetes and already have cardiovascular disease. Taking this medicine regularly along with proper diet and exercise will help you live a normal, healthy life. You should keep using it for as long as it is prescribed because it is protecting your future health.
Side effects of Glimfra MV Tablet ERThe majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you�re worried about them Common side effects of Glimfra MVNausea Diarrhea Abdominal pain Hypoglycemia (low blood glucose level)Loss of appetite
How to use Glimfra MV Tablet ERFollow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Glimfra MV 2 Tablet ER is to be taken empty stomach.
How Glimfra MV Tablet ER works Glimfra MV 2 Tablet ER is a combination of three antidiabetic medicines:.
Unsafe: Avoid consuming alcohol with Glimfra MV 2 Tablet ER as it is deemed unsafe.
Glimfra MV 2 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Glimfra MV 2 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Glimfra MV 2 Tablet ER is probably unsafe to use in patients with kidney disease and should be avoided. Doctor consultation is advised.Use of Glimfra MV 2 Tablet ER is, however, not recommended in patients with severe kidney disease.
Glimfra MV 2 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Glimfra MV 2 Tablet ER may be needed. Doctor consultation is advised.Glimfra MV 2 Tablet ER is generally started with low dose in patients with mild to moderate liver disease and its use is not recommended in patients with severe liver disease.
If a dose of Glimfra MV 2 Tablet ER is missed, take it promptly. However, if your next dose is approaching, skip the missed dose and resume your regular schedule. Avoid doubling the dose.
Glimepiride (08 Apr. 2019)
Metformin hydrochloride (08 Apr. 2019)
Dabhi AS, Bhatt NR, Shah MJ. Voglibose: An Alpha Glucosidase Inhibitor. J Clin Diagn Res. 2013;7(12):3023-7 (08 Apr. 2019)
Glimepiride+Metformin+Voglibose (25 Oct. 2021)
Metformin Hydrochloride (Prolonged Release), Voglibose & Glimepiride (28th Sept. 2023)
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.